These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23497767)

  • 1. Sitagliptin--another option for managing type 2 diabetes in dialysis patients?
    St Peter WL; Weinhandl ED; Flessner MF
    Am J Kidney Dis; 2013 Apr; 61(4):532-5. PubMed ID: 23497767
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary objective of study of sitagliptin in patients with ESRD on dialysis.
    Arjona Ferreira JC; Golm GT; Goldstein BJ
    Am J Kidney Dis; 2013 Sep; 62(3):642. PubMed ID: 23972060
    [No Abstract]   [Full Text] [Related]  

  • 3. In reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'.
    St Peter WL; Weinhandl ED; Flessner MF
    Am J Kidney Dis; 2013 Sep; 62(3):642-3. PubMed ID: 23972059
    [No Abstract]   [Full Text] [Related]  

  • 4. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
    Nomiyama T; Akehi Y; Takenoshita H; Nagaishi R; Terawaki Y; Nagasako H; Kudo T; Kodera T; Kobayashi K; Urata H; Yanase T;
    Diabetes Res Clin Pract; 2012 Feb; 95(2):e27-8. PubMed ID: 21899912
    [No Abstract]   [Full Text] [Related]  

  • 5. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Erol A
    Clin Ther; 2008 Apr; 30(4):785-6; author reply 786. PubMed ID: 18498926
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
    Arjona Ferreira JC; Corry D; Mogensen CE; Sloan L; Xu L; Golm GT; Gonzalez EJ; Davies MJ; Kaufman KD; Goldstein BJ
    Am J Kidney Dis; 2013 Apr; 61(4):579-87. PubMed ID: 23352379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection.
    Satoh K
    Circ J; 2013; 77(5):1156-7. PubMed ID: 23386273
    [No Abstract]   [Full Text] [Related]  

  • 8. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
    Bhatt DL; Cavender MA
    JACC Heart Fail; 2014 Dec; 2(6):583-5. PubMed ID: 24998081
    [No Abstract]   [Full Text] [Related]  

  • 9. Sitagliptin: a viewpoint by Mark S. Kipnes.
    Kipnes MS
    Drugs; 2007; 67(4):598-9. PubMed ID: 17352517
    [No Abstract]   [Full Text] [Related]  

  • 10. Should we be reassured about sitagliptin?
    Segal J
    BMJ; 2013 May; 346():f3051. PubMed ID: 23674336
    [No Abstract]   [Full Text] [Related]  

  • 11. [Incretin enhancer: sitagliptin].
    Kondo M; Tanizawa Y
    Nihon Rinsho; 2011 May; 69(5):859-63. PubMed ID: 21595272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?
    de Oliveira JM
    BMJ; 2013 Jun; 346():f3568. PubMed ID: 23737277
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
    Stafford S; Elahi D; Meneilly GS
    J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
    [No Abstract]   [Full Text] [Related]  

  • 15. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
    Skalli S; Wion-Barbot N; Baudrant M; Lablanche S; Benhamou PY; Halimi S
    Diabet Med; 2010 Apr; 27(4):486-7. PubMed ID: 20536525
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
    Fang V; Wazny LD; Raymond CB
    CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
    Acuña C
    Drugs Today (Barc); 2010 Dec; 46 Suppl F():1-12. PubMed ID: 21240332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.
    Kripke C
    Am Fam Physician; 2009 Mar; 79(5):372. PubMed ID: 19275065
    [No Abstract]   [Full Text] [Related]  

  • 19. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
    Perusicová J
    Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.
    Neumiller JJ; Odegard PS; White JR; Setter SM; Campbell RK
    Diabetes Educ; 2008; 34(2):183-200. PubMed ID: 18375772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.